Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression

BACKGROUND: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial of rilotumumab±epirubicin/cisplatin/capecitabine in gastric or oesophagogastric junction cancer, patients receiving rilotumumab showed a trend towards improved survival,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, M, Tang, R, Doshi, S, Oliner, K S, Dubey, S, Jiang, Y, Donehower, R C, Iveson, T, Loh, E Y, Zhang, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453660/
https://www.ncbi.nlm.nih.gov/pubmed/25584489
http://dx.doi.org/10.1038/bjc.2014.649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453660/
https://www.ncbi.nlm.nih.gov/pubmed/25584489
http://dx.doi.org/10.1038/bjc.2014.649

Ejemplares similares